[Synergistic interactions of TRAIL and paclitaxel on the laryngeal squamous carcinoma cell line in vitro].
OBJECTIVE
To investigate the synergistic cytotoxicity of TRAIL and paclitaxel on laryngeal squamous carcinoma cell line Hep-2.


METHODS
Hep-2 cells were exposed to various concentrations of TRAIL and paclitaxel respectively or jointly. The inhibition rate was measured by CCK-8 assay. The apoptosis rate and the expressions of DR4, DR5, DcR1 and DcR2 in Hep-2 cells were detected by flow cytometry methods.


RESULTS
Hep-2 cells were resistant to apoptosis induced by TRAIL. Paclitaxel could enhance its sensitivity to TRAIL by up-regulating the expressions of TRAIL death receptors in Hep-2 cells.


CONCLUSIONS
The resistance of Hep-2 cell to TRAIL could be overcome by paclitaxel. TRAIL and paclitaxel have synergistic killing effects on Hep-2 cells, so they might have a promising prospect in clinical therapy of laryngeal squamous carcinoma.
Zhang
Ming
M
Department of Otolaryngology, Eye Ear Nose Throat Hospital, Fudan University, Shanghai, 200031, China.
Zhou
Liang
L
Xie
Ming
M
Tian
Jie
J
D017209:Apoptosis / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D045744:Cell Line, Tumor; D004357:Drug Synergism; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000494:pharmacology*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000494:pharmacology*
D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D017239:Paclitaxel